← All Nanobiotix SA filings

Nanobiotix SA 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
NBTX
Nanobiotix SA
20-F: Nanobiotix 2025 Annual Report: Strategic Shifts & Royalty Financing
Nanobiotix's 2025 annual report highlights a significant revenue increase driven by a Janssen agreement amendment, new royalty financing, and ongoing clinical trial advancements for its lead product candidate, NBTXR3.
NASDAQ
NBTX
Nanobiotix SA
20-F: Nanobiotix S.A. Reports Fiscal Year 2024 Results, Highlights Janssen Partnership and Clinical Progress
Nanobiotix S.A. files its 20-F annual report, detailing financial results for the year ended December 31, 2024, and highlighting its strategic partnership with Janssen and ongoing clinical trials.
NASDAQ
NBTX
Nanobiotix SA
20-F: Nanobiotix and Johnson & Johnson Innovation Enter Registration Rights Agreement
Nanobiotix and Johnson & Johnson Innovation enter into a registration rights agreement, outlining terms for potential resale of Nanobiotix shares.